-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, S09IvruvU1mx6588tESmdy4pNCbMEMU9iQ6dkXvC0TiJZarPT82tweVb5LrXZnvm Q4s3YYuku7mAkFIXRo8GGA== 0001144204-07-069023.txt : 20071226 0001144204-07-069023.hdr.sgml : 20071225 20071226060526 ACCESSION NUMBER: 0001144204-07-069023 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20071205 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers FILED AS OF DATE: 20071226 DATE AS OF CHANGE: 20071226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NPS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000890465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 870439579 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-23272 FILM NUMBER: 071324802 BUSINESS ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 BUSINESS PHONE: (908) 450-5300 MAIL ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 8-K/A 1 v098077_8ka.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 8-K/A

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 5, 2007
 
NPS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Its Charter)

 
Delaware
0-23272
87-0439579
(State or other jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
 
 
550 Hills Drive, 3rd Floor
Bedminster, NJ 07921
  
(Address of principal executive offices)
 
(908) 450-5300
  
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 
Item 5.02  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
This Form 8-K/A is being filed to amend the Current Report on Form 8-K filed by NPS Pharmaceuticals, Inc. on December 11, 2007 to correct the cash value of the one-time stock award granted to Gerard J. Michel on December 5, 2007, was which was inadvertently reported as $92,304. The actual cash value of Mr. Michel’s stock award was $184,607.
 
 
 
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
 
NPS PHARMACEUTICALS, INC.
 
 		  
 		  
 
Date: December 21, 2007 By:   /s/ Andrew Rackear
 
Andrew Rackear, Senior Vice President, Legal Affairs, General Counsel and Secretary

 
 
 
 -----END PRIVACY-ENHANCED MESSAGE-----